Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China.
Department of Intervention, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China.
World J Gastroenterol. 2024 Jun 7;30(21):2751-2762. doi: 10.3748/wjg.v30.i21.2751.
Inflammatory bowel disease (IBD) is believed to be caused by various factors, including abnormalities in disease susceptibility genes, environmental factors, immune factors, and intestinal bacteria. Proton pump inhibitors (PPIs) are the primary drugs used to treat acid-related diseases. They are also commonly prescribed to patients with IBD. Recent studies have suggested a potential association between the use of certain medications, such as PPIs, and the occurrence and progression of IBD. In this review, we summarize the potential impact of PPIs on IBD and analyze the underlying mechanisms. Our findings may provide insights for conducting further investigations into the effects of PPIs on IBD and serve as an important reminder for physicians to exercise caution when prescribing PPIs to patients with IBD.
炎症性肠病(IBD)被认为是由多种因素引起的,包括疾病易感性基因、环境因素、免疫因素和肠道细菌的异常。质子泵抑制剂(PPIs)是治疗酸相关疾病的主要药物。它们也常用于治疗 IBD 患者。最近的研究表明,某些药物(如 PPIs)的使用与 IBD 的发生和进展之间可能存在关联。在这篇综述中,我们总结了 PPIs 对 IBD 的潜在影响,并分析了潜在的机制。我们的研究结果可能为进一步研究 PPIs 对 IBD 的影响提供了思路,并提醒医生在为 IBD 患者开具 PPIs 时要谨慎。